No profile data available.
Scorpius Holdings, Inc. (SCPX) is a healthcare company in the drug manufacturing contractors industry, based in San Antonio, United States, with about 90 full-time employees.
It reported revenue of $6.24 million for fiscal year 2024, down 10.7% from fiscal year 2023, and net income of -$32.81 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $229,842, down 75.1% from a year before. Its market capitalization was $12,228 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
, through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities.
Scorpius reported $6.24 million in revenue for fiscal year 2024, down 10.7% from $6.99 million in fiscal year 2023. In Q3 2025 revenue was $229,842.
$12,228 as of October 8, 2026.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include Orgenesis Inc. (ORGS), Scinai Immunotherapeutics Ltd. (SCNI), Qian Yuan Baixing, Inc. (QYBX).